Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100005, China
NCT Number: NCT05834361
Artificial abortion is the most widely used procedure in termination of first-trimester pregnancy. Cervical ripening before the operation guarantees operative convenience and decreases complications. An overstrained cervical dilation associates with uterine perforation, cervical laceration and cervical incompetence. To address the issue, various mechanical and pharmaceutical methods have been applied to prepare the cervix before transvaginal procedures. Prostaglandin analogues (PGs) play an important role in ripening the cervix or promoting uterine contraction in gynecology and obstetrics. As most tissues express prostaglandin receptors, vomiting, nausea, fever, diarrhea and abdominal pain can hardly be avoided with PGs administration. Longer PGs action contributes to better cervical ripening, but more uncomfortableness at the same time. These annoying symptoms may affect the participants' satisfaction and increase perioperative risks. To balance the safety and effectiveness of the surgery as well as patients' feeling, a proper timing for cervical ripening should be investigated. However, the administration timing of PGs has not reached a broad consensus, ranging from 16 hours to 2 hours before surgery. Carboprost methylate (CM), a PG-F2α analogue, has been used nationwide for cervical ripening in China. To minimize the side effects of PGs without affecting cervical ripening, the investigators intended to explore shortening the action time of CM in cervical preparation before artificial abortion. Thus, the investigators conducted this prospective cohort study and aimed to examine the efficacy of early and delayed vaginal administration of CM before surgery, and optimized both the perioperative safety and participants' convenience. The investigators hypothesize that early vaginal administration of CM would not affect the cervical ripening status, but will greatly reduce the unpleasant complications among the participants.
Looking for future studies?
Notify Me18 year–59 year
Female
Interventional
Not applicable
Beijing, Beijing Municipality, 100005, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
In this group, the administration time point of carboprost methylate is 20 minutes before the surgery.
In this group, the administration time point of carboprost methylate is usually 110-120 minutes before the surgery.
Time frame: Baseline (Before surgery)
total adverse events before anesthesia, including abdominal pain, nausea, vomiting, defecate desire and diarrhea.
Time frame: Baseline (Before surgery)
NRS score before surgery (score from 0-10)(0 = no pain; 10 = worst pain imaginable)
Time frame: 4 hours after surgery
The pond percentage
Peking Union Medical College Hospital
Other
The Administration Time Point of Carboprost Methylate and Effects on Perioperative Complications and Cervical Ripening Effect in Artificial Abortion
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05676294
Nausea, Pathologic Processes
New Haven, Connecticut, United States
View Trial DetailsNCT06899217
Abdominal Pain, Digestive System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT07688629
Female Urogenital Diseases and Pregnancy Complications, Morning Sickness
Antalya, Muratpaşa, Turkey (Türkiye)
View Trial DetailsNCT07540169
Chemotherapy-induced Nausea and Vomiting, Digestive System Diseases
Van, Tuşba, Turkey (Türkiye)
View Trial Details